Ultrasound-guided Quadro-Iliac Plane block for pain after total hip replacement
Effectiveness of Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty: A Prospective Randomized Study
This trial will test whether an ultrasound-guided Quadro-Iliac Plane (QIP) block reduces opioid use and pain in adults having elective primary total hip arthroplasty.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Bursa City Hospital Government |
| Locations | 1 site (Bursa) |
| Trial ID | NCT07410000 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized, double-blind trial comparing an ultrasound-guided Quadro-Iliac Plane (QIP) block to a sham saline injection in adults aged 18–80 with ASA I–III undergoing elective primary total hip arthroplasty. Participants receive either 40 mL of 0.25% local anesthetic with epinephrine delivered to the QIP plane or 40 mL of saline using the same technique, with blinding of patients and outcome assessors. The primary outcome is total opioid consumption during the first 24 postoperative hours, and secondary outcomes include motor block, dermatomal sensory assessment, pain scores, rescue analgesic use, QoR-15 recovery scores, and opioid-related side effects. Patients with contraindications to regional anesthesia or chronic opioid use are excluded to ensure safety and clear interpretation of analgesic effects.
Who should consider this trial
Good fit: Adults aged 18–80 years with ASA physical status I–III scheduled for elective primary total hip arthroplasty who are not chronic opioid users and have no contraindications to regional anesthesia are ideal candidates.
Not a fit: Patients with chronic opioid use, prior hip surgery, coagulopathy, infection at the injection site, severe cardiac/hepatic/renal disease, pregnancy or breastfeeding, or severe neurologic/psychiatric disorders are excluded and unlikely to receive benefit from enrollment.
Why it matters
Potential benefit: If successful, the QIP block could reduce opioid requirements and improve postoperative pain control and recovery after hip replacement.
How similar studies have performed: Related fascial plane blocks such as fascia iliaca and quadratus lumborum blocks have often shown reductions in postoperative pain and opioid use, but the QIP block is recently described and has limited prior clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) classification I-III * Age between 18 and 80 years * Patients scheduled for elective primary total hip arthroplasty Exclusion Criteria: * Refusal to participate in the study * Allergy to local anesthetics or opioids * Known or suspected coagulopathy * Infection at the injection site * History of previous hip surgery * Severe cardiovascular disease * Liver or kidney failure * Pregnancy, suspected pregnancy, or breastfeeding * Severe neurological or psychiatric disorder * Chronic opioid use
Where this trial is running
Bursa
- Bursa City Hospital — Bursa, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Mursel Ekinci, Assoc prof,MD
- Email: drmurselekinci@gmail.com
- Phone: +905067137596
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.